Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon said today it won FDA approval for its Surgicel powder absorbable hemostat designed as an adjunctive hemostatic solution to control continuous oozing on broad or raw surfaces.
The Surgicel powdered hemostat is comprised of oxidized regenerated cellulose, the base component in all of its Surgicel products. The powdered solution comes with an applicator and is designed to penetrate through oozing blood and form clots that stay intact even when the surgical field is irrigated, Ethicon said.
“This new and innovative approach to applying ORC, combined with the proven track record of the Surgicel brand, will give surgeons an ideal solution to control oozing bleeding on broad surfaces during surgeries,” Ethicon biosurgery platform lead Oray Boston said in a press release.
Last month, Ethicon released the results from 2 economic analyses of its Dermabond Prineo skin closure system, touting improved patient outcomes and lower healthcare costs.
The Dermabond Prineo skin closure system combines topical skin adhesive with a self-adhering patch, the company said.